Denise M. Ney is Billings Bascom Professor of Nutritional Sciences at the University of Wisconsin-Madison. Denise's research addresses two areas: gastrointestinal physiology with emphasis on the neuroendocrine regulation of intestinal adaptation and treatment of short bowel syndrome and the nutritional management of phenylketonuria using glycomacropeptide, a protein found in cheese whey that is naturally low in phenylalanine.
Michael Camilleri, M.D., is a consultant in the Division of Gastroenterology and Hepatology at Mayo Clinic and is professor of medicine, pharmacology, and physiology at Mayo Clinic College of Medicine in Rochester, MN. He currently serves as executive dean for the Department of Development. He received his M.D. degree from University of Malta Medical School and completed residency at St. Luke's University Hospital in Malta. He completed fellowships in research and internal medicine and gastroenterology at Hammersmith Hospital at the University of London, England, and at Mayo Graduate School in both research and clinical studies in gastroenterology. His research interests include clinical enteric neurosciences, gut neurohormonal control, obesity, irritable bowel syndrome, and pharmacology and pharmacogenomics. He is principal investigator and coinvestigator on research funded by the National Institute of Diabetes and Digestive and Kidney Diseases. He has published extensively in high-impact scientific journals such as New England Journal of Medicine, Gastroenterology, American Journal of Physiology, Neurogastroenterology and Motility, Gut, and American Journal of Gastroenterology. Dr. Camilleri is currently president of the American Gastroenterological Association.
Eugene B. Chang, M.D., is the Martin Boyer Professor of Medicine and Director of the Inflammatory Bowel Disease Research Center in Biological Sciences Division of the University of Chicago. Dr. Chang received his Medical Degree and conducted his Internship, Residency and Fellowship and the University of Chicago. He is board certified in Internal Medicine and Gastroenterology. Chang has been studying host-microbial interactions of the intestine, particularly in defining communication signals/pathways that are involved in maintaining intestinal homeostasis. These studies are also aimed at better understanding how perturbations or types of enteric microbiota contribute to the development of complex immune and metabolic diseases, especially inflammatory bowel diseases (IBD). As part of his research, Chang has defined several novel mechanisms and mediators of action of gut microbes that are currently being developed as therapeutic agents. For instance, one of the major actions of the enteric microbes is the maintenance of intestinal, epithelial stress proteins inherently important for enhancing cellular protection against immune/inflammatory stress, inhibiting apoptosis, and suppressing intestinal inflammation. The expression and function of these stress proteins are diminished in active IBD due to the development of dysbiosis, rendering the gut more susceptible to injury and stress. The identification of key immune and metabolic modulators produced by gut microbes could provide a means of restoring intestinal homeostasis to reduce the immune and inflammatory process and promote tissue protection and wound healing in IBD.
Andrew Giraud, Professor and Research Director, Infection and Immunity Division, Murdoch Childrens Research Institute (MCRI), Royal Childrens Hospital, Australia. Andy Giraud trained in zoology at Monash University, then cell biology at the University of Melbourne, and subsequently in gastrointestinal pathology and endocrinology in the Physiological Laboratory, University of Liverpool, UK, and at the University of California, Los Angeles, USA. His research interest is in understanding the mechanisms underlying inflammatory diseases of the gut like gastric cancer and eosinophilic esophagitis and is particularly focused on mouse genetic models. He is director of Infection and Immunity research at MCRI (17 groups), and coleads the gastrointestinal research in inflammation & pathology group, investigating key signaling pathways linking inflammation and gastric cancer and mechanisms of cross regulation between the epithelium and the innate immune system, and developing new therapeutics that block oncogenic development. His group has published a series of papers on this work in the high-impact journals Nature Medicine and Gastroenterology over the last 12 years.
Stephen J. Pandol, M.D. Dr. Stephen Pandol is the director of basic and translational pancreatic research at Cedars-Sinai Medical Center. He is a noted expert in pancreatic cellular physiology and mechanism of the disease. In his position he is responsible for organizing research efforts to develop potential therapies for pancreatic diseases, including pancreatitis (inflammation of the pancreas), pancreatic cancer, and diabetes. The research efforts encompass projects to determine basic mechanisms of disease and projects using this information to develop new therapies including prevention. The team of researchers include scientists with skills chemistry and biology to those conducting clinical trials in patients using new agents developed by the group.
Harry Pothoulakis, MD. Dr. Pothoulakis is a Professor of Medicine, Pathology, and Laboratory Medicine and the Eli and Edythe Broad Chair of Medicine at the University of California at Los Angeles. He is also the Chair of Research at the Division of Digestive Diseases and the Director of the IBD Research Center at UCLA. His research is primarily focused on the role of neuropeptides and hormones in the pathophysiology of several gastrointestinal disease states, including IBD, infectious diarrhea, and IBS.
Natalie J. Torok received her MD degree at the Semmelweis School of Medicine in Budapest, Hungary. Her post-doctoral training included the Laval University, Quebec and the Mayo Clinic, Rochester where she also completed her residency and fellowship in Gastroenterology. She was recruited to the University of California, where she is currently Professor in Gastroenterology and Hepatology. Her research focuses on the mechanisms of liver fibrogenesis specifically on the role of oxidative stress in non-alcoholic and alcoholic steatohepatitis.
Nathalie Vergnolle is a director of research at the French Institute of Health and Medical Research (INSERM). She has worked on gastrointestinal pathologies for years and has gained international recognition with her work on some of the mediators involved in inflammation and pain. She has been studying the role of intestinal epithelium in IBD and in IBS with a particular focus on the relationship between epithelia-derived mediators and enteric neurons activation.